TumCG Cancer Research Results

TumCG, Tumor cell growth: Click to Expand ⟱
Source:
Type:
Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M).
Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division).
Scientific Papers found: Click to Expand⟱
3033- RosA,    Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP - vitro+vivo, NA, NA
ER Stress↑, selectivity↑, AR↓, TumCG↓, TumCCA↑, CHOP↑, PERK↓, GRP78/BiP↑, PSA↓,
3639- Sage,    Pharmacological properties of Salvia officinalis and its components
- Review, AD, NA - Review, Var, NA
AntiCan↑, *Inflam↓, *antiOx↑, *cognitive↑, *memory↑, *LDL↓, TumCG↓, MAPK↓, ROS↓, NF-kB↓, COX2↓, angioG↓, *AST↓, *ALAT?,
2040- SAHA,    The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
- in-vitro, Pca, LNCaP - in-vitro, CRC, T24/HTB-9 - in-vitro, BC, MCF-7
HDAC↓, TumCG↓, Diff↑, Apoptosis↑, TXNIP↑,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27↑, CHOP↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
4902- Sal,  OXA,    Salinomycin and oxaliplatin synergistically enhances cytotoxic effect on human colorectal cancer cells in vitro and in vivo
- vitro+vivo, CRC, NA
RadioS↑, ChemoSen↑, TumCP↓, Apoptosis↑, ROS↑, MMP↓, MAPK↑, eff↓, TumCG↓, TumCCA↑,
4903- Sal,    Salinomycin: A new paradigm in cancer therapy
- Review, Var, NA
TumCG↓, ATP↓, CSCs↓, ROS↑, Casp↑, MMP↓, selectivity↑, OXPHOS↓, STAT3↓, P53↑, γH2AX↑, cycD1/CCND1↓, TumCCA↑, DNAdam↑, ChemoSen↑,
4995- Sal,    Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway
- vitro+vivo, BC, MDA-MB-231
ALDH↓, Nanog↓, OCT4↓, SOX2↓, CSCs↓, tumCV↓, cycD1/CCND1↓, P21↑, TumCG↓, CD44↓, Apoptosis∅,
4909- Sal,    Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model
- vitro+vivo, CRC, NA
AntiTum↑, Apoptosis↑, mtDam↑, ROS↑, SOD1↓, ChemoSen↑, CSCs↑, ALDH↓, TumCG↓, TumCP↓, TumCD↑, ATP↓,
5123- Sal,    Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells
- in-vitro, BC, MCF-7 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, HEK293
Wnt↓, β-catenin/ZEB1↓, mTORC1↓, GSK‐3β↑, cycD1/CCND1↓, survivin↓, LRP6↓, TumCG↓, Apoptosis↑,
5122- Sal,    Identification of selective inhibitors of cancer stem cells by high-throughput screening
- in-vivo, BC, SUM159 - NA, NA, 4T1
CSCs↓, TumCG↓, Diff↑, selectivity↑, CD44↓, CD24↓, TumVol↓,
5044- SAS,    xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma
- in-vitro, Var, NA
xCT↓, Ferroptosis↑, ROS↑, IL1↓, IL2↓, NF-kB↓, GSH↓, TumCG↓, ChemoSen↑,
5042- SAS,    xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
- Review, Var, NA
xCT↓, GSH↓, TumCG↓, TumCI↓, ROS↑, RadioS↑, eff↓,
5041- SAS,  Cisplatin,    Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
- in-vitro, CRC, NA
xCT↓, Inflam↓, Apoptosis↓, GSH↓, ROS↑, TumCG↓, selectivity↑, eff↑, eff↓,
5039- SAS,    Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer
- vitro+vivo, BC, NA
xCT↓, ROS↑, GSH↓, Ferroptosis↑, TumCG↓, toxicity↓, lipid-P↑,
5036- SAS,    Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
xCT↓, GSH↓, OS↑, Myc↓, CDK1↓, CD44↓, eff↑, TumCG↓,
4486- Se,  Chit,    Selenium-Modified Chitosan Induces HepG2 Cell Apoptosis and Differential Protein Analysis
- in-vitro, Liver, HepG2
Apoptosis↑, TumCCA↑, MMP↓, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Risk↓, *BioAv↑, *toxicity↑, TumCG↓, AntiTum↑, ROS↑, Cyt‑c↑, Fas↑, FasL↑, FADD↑,
4734- SeNPs,  CPT-11,    Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles
- in-vitro, CRC, HCT8 - in-vivo, NA, NA
chemoP↑, ChemoSen↑, P53↑, Apoptosis↑, TumCG↓, Casp↑, Dose↝, NRF2↓, selectivity↑, *NRF2↑,
4469- SeNPs,    Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential
- Review, Var, NA
antiOx↑, selectivity↑, eff↑, AntiCan↑, Apoptosis↑, ROS↑, MMP↓, Casp3↑, Casp9↑, AntiTum↑, TumCG↓, TumMeta↓, angioG↓, Cyt‑c↑, DNAdam↑, RadioS↑, BBB↑, *toxicity↓, ChemoSen↑,
3193- SFN,    Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress
- Review, Var, NA
DNMTs↓, HDAC↑, NRF2↑, DNMT1↓, DNMT3A↓, NQO1↑, COMT↑, TumCG↓, *toxicity↓,
110- SFN,    Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway
- in-vivo, PC, NA
HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, VEGF↓, PDGFRA↓, EMT↓, Zeb1↓, Bcl-2↓, XIAP↓, E-cadherin↑, OCT4↓, Nanog↓, TumCG↑,
2552- SFN,  Chemo,    Chemopreventive activity of sulforaphane
- Review, Var, NA
chemoPv↑, TumCG↓, *ROS↓, *Inflam↓, *Dose↝, *NRF2↑, *HO-1↑, *NQO1↑, NF-kB↓, ROS↑,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1736- SFN,    Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models
- in-vitro, BC, NA - in-vivo, BC, NA
TumCG↓, selectivity↓,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1453- SFN,    Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCP↓, TumCCA↑, H3↑, H4↑, HDAC↓, CDK1↑, CDK2↑, p19↑, *BioAv↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1474- SFN,    Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway
- in-vitro, Colon, SW480
TumCG↓, Apoptosis↑, MMP↓, Bax:Bcl2↑, Casp3↑, Casp7↑, Casp9↑, ROS↑, e-ERK↑, p38↑, P53∅, eff↓, ChemoSen↑,
1507- SFN,    Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects
- in-vivo, Colon, NA - Human, Nor, NA
TumCG↓, HDAC↓, *BioAv↑, Dose∅, Half-Life∅,
1484- SFN,    Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action
- Review, Var, NA - Review, AD, NA
neuroP↑, AntiCan↑, NRF2↑, HDAC↓, eff↑, *ROS↓, neuroP↑, HDAC↓, *toxicity∅, BioAv↑, eff↓, cycD1/CCND1↓, CDK4↓, p‑RB1↓, Glycolysis↓, miR-30a-5p↑, TumCCA↑, TumCG↓, TumMeta↓, eff↑, ChemoSen↑, RadioS↑, CardioT↓, angioG↓, Hif1a↓, VEGF↓, *BioAv?, *Half-Life∅,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓, Apoptosis↑, Casp3↑, PARP↑, TumCG↓,
1140- SIL,    Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
- in-vitro, PC, AsPC-1 - in-vivo, PC, NA - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
2410- SIL,    Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vivo, NA, NA
TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,
2356- SK,    ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment
- in-vitro, Ovarian, CaOV3 - in-vitro, Ovarian, OV90 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, FASN↓, lactateProd↓, Warburg↓, TumCG↓, VM↓,
2357- SK,    GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism
- Study, HCC, NA - in-vivo, NA, NA
AntiTum↑, GTPBP4↓, PKM2↓, lactateProd↓, GlucoseCon↓, Glycolysis↓, E-cadherin↑, TumCG↓,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,
2228- SK,    Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT15 - in-vivo, NA, NA
Apoptosis↑, Bcl-2↓, Casp3↑, Casp9↑, cl‑PARP↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, CHOP↑, JNK↑, eff↓, ER Stress↑, ROS↑, TumCG↓,
2219- SK,    Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways
- in-vitro, Nor, HaCaT
*MMP↓, *ROS↑, *Casp3↑, *TumCG↓,
2212- SK,    Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways
- in-vitro, AML, NA
FLT3↓, NF-kB↓, miR-155↓, Diff↑, TumCG↓,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
5102- SK,  GEM,    Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway
TumCG↓, ChemoSen↑, NF-kB↓, PCNA↓, Ki-67↓, p‑EGFR↓, ROS↑, TumCCA↑, P53↑, JNK↑, Akt↓,
5100- SK,    Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression
- vitro+vivo, NPC, NA
TumCP↓, RIP1↑, ROS↑, Necroptosis↑, Casp3↑, Casp8↑, eff↓, TumCG↓,
1343- SK,    Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis
- in-vitro, Ovarian, A2780S - in-vivo, NA, A2780S
*BioAv↓, ROS↑, GSH↓, TumCG↓,
2009- SK,    Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer
- in-vitro, Bladder, NA
TumCG↓, selectivity↑, *toxicity∅, Necroptosis↑, ROS↑, p62↑, Keap1↑, *NRF2↑, eff↑,
977- SK,    A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, HMEC
TumCG↓, ERα/ESR1↓, selectivity↑, *toxicity↓,

Showing Research Papers: 501 to 550 of 598
Prev Page 11 of 12 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 598

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Ferroptosis↑, 2,   GSH↓, 7,   H2O2↑, 1,   Keap1↑, 1,   lipid-P↑, 1,   NQO1?, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 3,   OXPHOS↓, 1,   OXPHOS↑, 1,   mt-OXPHOS↓, 1,   ROS↓, 2,   ROS↑, 23,   mt-ROS↑, 1,   SOD1↓, 1,   xCT↓, 6,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 7,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 11,   MMP↑, 1,   mtDam↑, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   i-citrate↑, 1,   cMyc↓, 3,   FASN↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 8,   HK2↓, 3,   lactateProd↓, 5,   LDHA↓, 2,   PFKP↓, 1,   PKM2↓, 4,   PPP↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↓, 2,   Apoptosis↑, 16,   Apoptosis∅, 1,   Bak↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 8,   Bcl-xL↓, 3,   BIM↑, 1,   Casp↑, 4,   Casp3↑, 11,   cl‑Casp3↑, 2,   Casp7↑, 2,   Casp8↑, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   p‑Chk2↑, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 4,   DR4↑, 1,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 2,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 1,   Mcl-1↓, 2,   Myc↓, 2,   Necroptosis↑, 2,   necrosis↑, 1,   NOXA↑, 1,   p27↑, 2,   p38↑, 2,   p‑p38↓, 1,   RIP1↑, 1,   survivin↓, 4,   Telomerase↓, 1,   TumCD↑, 1,   TUNEL↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 2,  

Transcription & Epigenetics ⓘ

H3↑, 1,   ac‑H3↑, 1,   H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-30a-5p↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 2,   PERK↓, 1,   PERK↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↝, 1,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 4,   DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↑, 5,   P53∅, 1,   p‑P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 3,   PCNA↓, 2,   γH2AX↑, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK1↑, 1,   CDK2↑, 1,   CDK4↓, 2,   CDK4↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 8,   cycE/CCNE↓, 1,   p19↑, 1,   P21↑, 6,   p‑RB1↓, 1,   TumCCA↑, 14,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 3,   CD24↓, 1,   CD44↓, 4,   CSCs↓, 5,   CSCs↑, 1,   Diff↑, 3,   EMT?, 1,   EMT↓, 6,   ERK↓, 2,   ERK↑, 1,   p‑ERK↓, 1,   e-ERK↑, 1,   FLT3↓, 1,   FOXO3↑, 1,   Gli1↓, 4,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   GTPBP4↓, 1,   HDAC↓, 8,   HDAC↑, 1,   HH↓, 2,   IGFBP3↑, 1,   LRP6↓, 1,   mTOR↓, 2,   mTORC1↓, 1,   Nanog↓, 2,   NOTCH↓, 1,   OCT4↓, 2,   PDGFRA↓, 1,   PI3K↓, 1,   PTCH1↓, 1,   Shh↓, 2,   Smo↓, 3,   SOX2↓, 1,   STAT3↓, 4,   p‑STAT3↓, 2,   TumCG↓, 48,   TumCG↑, 1,   Wnt↓, 4,  

Migration ⓘ

CA↓, 1,   Ca+2↑, 2,   E-cadherin↑, 4,   FAK↓, 1,   GLI2↓, 3,   Ki-67↓, 3,   miR-155↓, 1,   miR-203↑, 1,   MMP2↓, 4,   MMP9↓, 4,   N-cadherin↓, 1,   PDGF↓, 1,   Slug↓, 1,   Snail↓, 2,   TGF-β↓, 3,   TumCI↓, 5,   TumCMig↓, 3,   TumCP↓, 9,   TumMeta↓, 5,   Twist↓, 1,   TXNIP↑, 1,   uPA↓, 1,   Vim↓, 2,   Zeb1↓, 3,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 7,   ATF4↑, 1,   EGFR↓, 2,   p‑EGFR↓, 1,   eNOS↓, 1,   Hif1a↓, 7,   VEGF↓, 7,   VEGFR2↓, 1,   VM↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 1,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   CXCR4↓, 1,   IL1↓, 2,   IL1β↓, 1,   IL2↓, 1,   IL6↓, 2,   Inflam↓, 2,   JAK1?, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 1,   NF-kB↓, 8,   PD-L1↓, 2,   PGE2↓, 2,   PSA↓, 2,  

Cellular Microenvironment ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   COMT↑, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 2,   ChemoSen↑, 12,   Dose↝, 3,   Dose∅, 1,   eff↓, 11,   eff↑, 12,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 4,   selectivity↓, 1,   selectivity↑, 10,  

Clinical Biomarkers ⓘ

AR↓, 3,   EGFR↓, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   HER2/EBBR2↓, 2,   IL6↓, 2,   Ki-67↓, 3,   Myc↓, 2,   PD-L1↓, 2,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 4,   AntiTum↑, 4,   cachexia↓, 1,   cardioP↑, 1,   CardioT↓, 1,   chemoP↑, 3,   chemoPv↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   OS↑, 1,   radioP↑, 1,   Risk↓, 1,   Strength↑, 1,   toxicity↓, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 1,   Weight∅, 1,  
Total Targets: 263

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 2,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 4,   ROS↑, 1,   Trx↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT?, 1,   ALAT↓, 1,   LDL↓, 1,   PPARγ↑, 1,   SIRT1↑, 2,  

Cell Death ⓘ

Casp3↑, 1,   necrosis↓, 1,  

Protein Folding & ER Stress ⓘ

HSP27↑, 1,   HSPs↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

TIMP1↓, 1,  

Barriers & Transport ⓘ

GLUT4↑, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL1↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 4,   TNF-α↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv?, 1,   BioAv↓, 1,   BioAv↑, 3,   Dose↝, 1,   Half-Life∅, 1,  

Clinical Biomarkers ⓘ

ALAT?, 1,   ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   toxicity↓, 3,   toxicity↑, 1,   toxicity∅, 3,  
Total Targets: 43

Scientific Paper Hit Count for: TumCG, Tumor cell growth
26 Curcumin
25 Magnetic Fields
17 Phenethyl isothiocyanate
15 Quercetin
14 Berberine
13 Silver-NanoParticles
13 Chemotherapy
13 Sulforaphane (mainly Broccoli)
13 Shikonin
12 Vitamin C (Ascorbic Acid)
12 Magnetic Field Rotating
12 Bicarbonate(Sodium)
11 Alpha-Lipoic-Acid
11 Baicalein
11 EGCG (Epigallocatechin Gallate)
10 Capsaicin
10 Apigenin (mainly Parsley)
9 Silymarin (Milk Thistle) silibinin
9 Garcinol
8 Astragalus
8 Artemisinin
8 Resveratrol
8 Dichloroacetate
8 salinomycin
8 diet FMD Fasting Mimicking Diet
8 Phenylbutyrate
8 Pterostilbene
8 Urolithin
7 Allicin (mainly Garlic)
7 HydroxyCitric Acid
7 Ashwagandha(Withaferin A)
7 Boron
7 Boswellia (frankincense)
7 Gambogic Acid
6 Radiotherapy/Radiation
6 Metformin
6 Betulinic acid
6 immunotherapy
6 Coenzyme Q10
6 Deguelin
6 diet Methionine-Restricted Diet
6 Sulfasalazine
6 Magnolol
6 Lycopene
6 Magnesium
6 Rosmarinic acid
5 chitosan
5 Melatonin
5 Berbamine
5 Cisplatin
5 Chrysin
5 Gemcitabine (Gemzar)
5 Fisetin
5 Honokiol
5 Juglone
4 3-bromopyruvate
4 Astaxanthin
4 Atorvastatin
4 Brucea javanica
4 Butyrate
4 Caffeic Acid Phenethyl Ester (CAPE)
4 Citric Acid
4 Emodin
4 Luteolin
4 Piperine
4 Piperlongumine
4 Selenite (Sodium)
4 Thymoquinone
4 Vitamin K2
4 VitK3,menadione
3 Caffeic acid
3 doxorubicin
3 Paclitaxel
3 Baicalin
3 Bufalin/Huachansu
3 brusatol
3 Bruteridin(bergamot juice)
3 Carvacrol
3 Celastrol
3 Chlorogenic acid
3 Selenium NanoParticles
3 Photodynamic Therapy
3 Genistein (soy isoflavone)
3 Graviola
3 Hydrogen Gas
3 Niclosamide (Niclocide)
3 Propyl gallate
3 Plumbagin
3 Aflavin-3,3′-digallate
2 2-DeoxyGlucose
2 Auranofin
2 Fenbendazole
2 Andrographis
2 Ascorbyl Palmitate
2 Dipyridamole
2 Biochanin A
2 Bifidobacterium
2 Bromelain
2 Carnosic acid
2 Oxygen, Hyperbaric
2 diet Short Term Fasting
2 Disulfiram
2 Copper and Cu NanoParticles
2 Ellagic acid
2 Gallic acid
2 Galloflavin
2 tamoxifen
2 Hydroxycinnamic-acid
2 HydroxyTyrosol
2 Methylene blue
2 Oroxylin-A
2 Oleuropein
2 Orlistat
2 Psoralidin
2 Hyperthermia
2 Oxaliplatin
2 Spermidine
2 Ursolic acid
2 Whole Body Vibration
1 5-fluorouracil
1 Anzaroot, Astragalus fasciculifolius Bioss
1 octreotide
1 Diclofenac
1 Acetyl-l-carnitine
1 Anti-oxidants
1 5-Aminolevulinic acid
1 Aloe anthraquinones
1 beta-glucans
1 temozolomide
1 Bacopa monnieri
1 Caffeine
1 urea
1 Cat’s Claw
1 Cannabidiol
1 Celecoxib
1 Chocolate
1 Cinnamon
1 Calorie Restriction Mimetics
1 Bicalutamide
1 Dichloroacetophenone(2,2-)
1 Bortezomib
1 Docosahexaenoic Acid
1 diet Ketogenic
1 diet Plant based
1 Zinc
1 Evodiamine
1 PXD, phenoxodiol
1 Sorafenib (brand name Nexavar)
1 Electrical Pulses
1 erastin
1 Fucoidan
1 Shilajit/Fulvic Acid
1 Ginger/6-Shogaol/Gingerol
1 Glabrescione B
1 Grapeseed extract
1 Inositol
1 itraconazole
1 Ivermectin
1 Laetrile B17 Amygdalin
1 Licorice
1 mebendazole
1 metronomic chemo
1 Methylglyoxal
1 Mushroom Chaga
1 Naringin
1 Nimbolide
1 Noscapine
1 Parthenolide
1 raloxifen
1 Salvia officinalis
1 Vorinostat
1 Selenium
1 irinotecan
1 Salvia miltiorrhiza
1 Saikosaponin B1 and D
1 Sutherlandioside D
1 Taurine
1 Tomatine
1 Tumor Treating Fields
1 Vitamin B1/Thiamine
1 Vitamin B5,Pantothenic Acid
1 Transarterial Chemoembolization
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:323  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page